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Introduction
Allergic diseases constitute a significant cause of mor-
bidity worldwide and a considerable burden on the
health and medical systems of both developed and emer-
ging economies. Allergies and related diseases including
asthma, rhinosinusitis, atopic dermatitis and life threat-
ening food, drug, and stinging insect allergies affect at
least 30% of the population and nearly 80% of families.
According to recent studies, their prevalence is increas-
ing globally [1–4].
Medical services providing expert allergy care are lack-
ing in many countries; therefore, the major organizations
devoted to the field of allergy (American Academy of
Allergy, Asthma and Immunology, AAAAI; American
College of Allergy, Asthma, and Immunology, ACAAI;
European Academy of Allergy, Asthma and Clinical
Immunology, EAACI; and the World Allergy
Organization, WAO), strongly feel that education of
health professionals and the public on the importance
and impact of allergic diseases as a public health
concern should be encouraged.
The International Collaboration in Allergy, Asthma, and
Immunology (iCAALL), a partnership constituted by
AAAAI, ACAAI, EAACI, and WAO, have recommended
publishing an advocacy statement with the purpose of
calling to the attention of the medical community, health
authorities and the public in general, the major impact
and relevance of the allergy specialists as key groups of
professionals specifically trained for the adequate diagno-
sis, treatment, and prevention of allergic diseases.
Allergic diseases are often underdiagnosed and undertreated
Allergy is a rather “new” medical specialty, having only
emerged with increased awareness of immunologic re-
sponses and the increasing importance of non-
communicable diseases. However, in spite of being a
major global public health issue, the public and the
health establishment have generally not recognized the
importance of allergic diseases. Since the prevalence of
allergic diseases has been steadily increasing, it is time
to place the field of allergy in a more prominent place
within global medical organizations.
This absence of proper recognition frequently results in
a lack of, or incorrect, diagnosis resulting in sub-optimal
disease management, negative effects on quality of life, in-
creased morbidity and mortality, and considerable add-
itional direct and indirect costs. Moreover, the complexity
and involvement of multiple organs and systems of aller-
gic diseases confounds management in fragmented care
based on our current health care delivery systems
dependent on traditional organ-based specialists.
Unmet needs in allergic care
In most populations around the world there is a lack of
adequate education on the definition, etiology, pathogen-
esis, proper therapies, and prevention of allergic dis-
eases. Awareness of the morbidity and potential
mortality associated with allergic diseases, the chronic
nature of those conditions, and the importance of con-
sulting a physician knowledgeable in allergic diseases,
asthma and clinical immunology are often lacking. This
translates into patients with allergic diseases not being
managed by physicians with the necessary training and
skills in the appropriate use of efficacious medications
required for optimal management.
There is an increasing need to expand the number of
allergy/clinical immunology specialists as well as local
and regional diagnostic and treatment centers in order
to facilitate timely referrals for patients with complex
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allergic diseases. A goal should be established to guaran-
tee the universal accessibility to affordable and cost-
effective therapies as well as novel medications used in
the management of allergic diseases.
Presently, there are millions of people worldwide who
do not have access to care by specialists in allergy [1].
Moreover, epinephrine auto-injectors, some drugs for se-
vere asthma, allergen-specific immunotherapy, and some
drugs for adverse reactions to biologicals and chemo-
therapeutic agents in desensitization centers are not
available in many parts of the world.
Public health officers should provide for optimal al-
lergy/clinical immunology services, including access to
specialists and diagnostic and treatment centers. Aller-
gists should be able to prescribe the most cost-effective
medications to manage the specific clinical findings of
each allergic patient.
Consultations with allergists to assure correct diagno-
sis and treatment are indispensable to improve long-
term patient outcomes and their quality of life and re-
duce the unnecessary additional direct and indirect costs
passed on to the patient, payer and society.
In the last decade there have been important advances
in the field of allergy, especially in the understanding of
the mechanisms leading to disease, improved diagnostic
methods based in molecular allergy, and novel medica-
tions for immune modulation and immunotherapy based
in more effective and safe vaccines and biologicals [5–9].
What can be done to improve the current situation?
Advocacy from these professional organizations on the
role of allergy in public health has been identified as the
most important objective of iCAALL. Increasing aware-
ness on the relevance of allergic diseases as a major pub-
lic health problem could lead to a better recognition by
governments and health authorities.
Programs to increase awareness of allergic diseases
should focus on the causes, prevention, control, and eco-
nomic impact. The main goal would be better care of al-
lergic diseases around the world with the aim to
effectively engage regional, country, and local authorities.
An important step forward supported by the major al-
lergy organizations resides in current efforts to obtain
World Health Organization (WHO) recognition of al-
lergy through the new nomenclature of allergic diseases
included in the ICD-11 classification of diseases [10, 11].
Because allergic diseases are systemic multi-organ dis-
eases, allergists are in the best position to diagnose and
manage the allergic patient, in contrast to the classic
organ-based approach of most other medical specialties.
Allergic disease management by allergists based on the
new technological advancements could be more effica-
cious and cost-effective when compared to the care pro-
vided by generalists or other specialists.
In addition, allergists have significant experience in the
implementation of preventive measures which have been
shown to diminish or eliminate allergic symptoms, in-
cluding environmental control measures and allergen-
specific immunotherapy, which could reduce the costs
of disease management.
Focus on the patient
Educational efforts focused on allergic diseases should
be specifically directed to patients and their families as
the final targets of these awareness programs. In order
to obtain better results regarding disease prevention and
control, it will be strictly necessary to reach the commu-
nity at various levels, including regional, local, and state
agencies as well as schools and patient organizations
with straight forward and understandable messaging.
At the same time, approaching governments, politi-
cians and public health officers should be part of the
strategy in order to promote the allocation of sufficient
resources for the diagnosis, control, treatment and
prevention of allergic diseases.
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